GlassScriptPhysician profile
Vickram Tejwani
NPI 1578907978
$58,090.12
in general payments reported to CMS, 2019-2025
10 companies · $40K in 2025
The $40K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,254 · 2022: $141 · 2023: $409 · 2024: $15K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Consulting Fee: $9,853 · Travel and Lodging: $4,285 · Honoraria: $3,500 · Food and Beverage: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,823.13 |
| Consulting Fee | $9,853.00 |
| Travel and Lodging | $4,284.60 |
| Honoraria | $3,500.00 |
| Food and Beverage | $1,233.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $33,532.10 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $16,668.55 | 2023-2025 | Dupixent |
| Phadia US INC. | $2,500.00 | 2024 | Immunocap |
| Csl Behring | $2,254.36 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $1,874.83 | 2022-2025 | Fasenra |
| Cipla USA INC. | $1,000.00 | 2025 | |
| Verona Pharma, INC. | $247.65 | 2025 | Ohtuvayre |
| Inogen, INC. | $12.63 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vickram Tejwani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.